Sharon Hassin-Baer

Sharon Hassin-Baer

Auto-generated profile, based on publicly available information

Sharon Hassin-Baer

Movement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat Gan, Israel

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2004 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
YHYasuko Hatano
Yasuko Hatano
YLYuanzhe Li
Yuanzhe Li
KSKenichi Sato
Kenichi Sato
SAShuichi Asakawa
Shuichi Asakawa
YYYasuhiro Yamamura
Yasuhiro Yamamura
NHNobutaka Hattori
Nobutaka Hattori

15 March 2014 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
NKNatalie Kaplan
Natalie Kaplan
AVAya Vituri
Aya Vituri
AKAmos D. Korczyn
Amos D. Korczyn
OCOren S. Cohen
Oren S. Cohen
RIRivka Inzelberg
Rivka Inzelberg
SHSharon Hassin-Baer
Sharon Hassin-Baer

1 June 2004 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
SHSharon Hassin-Baer
Sharon Hassin-Baer
EKEilon D. Kirson
Eilon D. Kirson
LSLester Shulman
Lester Shulman
ABAron S. Buchman
Aron S. Buchman
HBHanna Bin
Hanna Bin
EMElla Mendelson
Ella Mendelson
Case Report from JAMA Neurology — Stiff-Person Syndrome Following West Nile Fever

15 March 2007 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
LELilach Ephraty
Lilach Ephraty
OPOmer Porat
Omer Porat
DIDavid Israeli
David Israeli
OCOren S. Cohen
Oren S. Cohen
OTOlga Tunkel
Olga Tunkel
SHSharon Hassin‐Baer
Sharon Hassin‐Baer

30 August 2004 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
LMLeo Verhagen Metman
Leo Verhagen Metman
BMBrian Myre
Brian Myre
NVNiek Verwey
Niek Verwey
SHSharon Hassin‐Baer
Sharon Hassin‐Baer
JAJean Arzbaecher
Jean Arzbaecher
RBRoy Bakay
Roy Bakay

1 February 2005 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
SHSharon Hassin-Baer
Sharon Hassin-Baer
ESEsther Scheuer
Esther Scheuer
ABAron S. Buchman
Aron S. Buchman
IJIzhak Jacobson
Izhak Jacobson
BBBruria Ben-Zeev
Bruria Ben-Zeev
The objective of this study was to evaluate the feasibility of ultrasonography-guided injections of botulinum toxin A into the parotid glands of children with severe drooling (sialorrhea). Excessive drooling is common in children with chronic neurologic disorders. Preliminary observations in adults suggest that injections of botulinum toxin A into the parotid glands can decrease drooling, but the optimal dose, sites of injection, and concomitant use of imaging during injections and its use for children have not been established. Ultrasonography was used to guide the injection of botulinum toxin (10—25 IU) into both parotid glands of nine children with excessive drooling. Subjective and objective measures of the severity of drooling were collected before and after botulinum toxin A injections. A booster injection was provided if the initial response was inadequate. Injections were well tolerated, and no adverse reactions were observed. Ultrasonography revealed that the parotid gland showed a variable depth, extent, and vascularization. Eight of nine patients needed a booster injection after 1 month. Objective measures of drooling severity were improved in seven of nine patients. However, subjective improvement was reported in only three of nine patients, and this improvement was functionally significant in only one patient. Although intraparotid injection of botulinum toxin A is safe and causes a reduction in saliva production in children, the doses used in this study did not result in functionally significant improvement. Higher doses of botulinum toxin A in the parotid glands or concomitant injections into the submandibular glands can increase the efficacy of these injections. Variability in size, depth, and vascular supply of the parotid gland suggests the importance of ultrasonography guidance for optimizing injections. These results underscore the need for further studies to establish the efficacy of this treatment in children. (J Child Neurol 2005;20:120—123).